Table 3.
The risk of impaired glucose regulation and type 2 diabetes associated with a 0.1 μg/l increase in serum OPG
| Model | Adjustment | IGR (n = 730) | p valuea | Impaired glucose regulation and type 2 diabetes (n = 1,057) | p valueb |
|---|---|---|---|---|---|
| Model 1 | Unadjusted | 1.143 (1.112–1.174) | <0.0001 | 1.146 (1.127–1.167) | <0.0001 |
| Model 2 | Adjusted for age, gender, current smoking, current alcohol intake and family history of diabetes | 1.137 (1.108–1.166) | <0.0001 | 1.141 (1.115–1.168) | <0.0001 |
| Model 3 | Further adjusted for BMI and waist/hip ratio, based on Model 2 | 1.134 (1.104–1.165) | <0.0001 | 1.136 (1.107–1.166) | <0.0001 |
| Model 4 | Further adjusted for HOMA-IR, based on Model 3 | 1.133 (1.103–1.164) | <0.0001 | 1.132 (1.103–1.161) | <0.0001 |
| Model 5 | Further adjusted for serum triacylglycerol, total cholesterol, HDL- and LDL-cholesterol, based on Model 4 | 1.108 (1.009–1.117) | 0.01 | 1.121 (1.101–1.141) | 0.0005 |
Values are ORs (95 % CI)
aFor the risk of IGR, we defined participants with normal glucose regulation as 0 (n = 599) and IGR as 1 (n = 730), excluding patients with type 2 diabetes (n = 327) from the analysis
bFor the risk of combined IGR and type 2 diabetes, we defined participants with NGR as 0 (n = 599) and combined IGR and type 2 diabetes as 1 (n = 1,057)